Ernexa Therapeutics Inc. (ERNA): Nasdaq/NYSE listing notice — Eterna receives Nasdaq non-compliance notice over board independence; has 45 days to submit plan

Ernexa Therapeutics Inc.

Received Nasdaq notice on Jan 17, 2024 for failing majority independent board and audit committee rules under Listing Rule 5605.
Triggered by appointment of Dorothy Clarke as GC and her resignation from board committees, plus Sanjeev Luther joining board.
Company has 45 days to submit a compliance plan; Nasdaq may grant up to 180-day extension.
No immediate effect on listing; common stock continues trading under symbol ERNA.
Company is evaluating director candidates to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: board independence
Rules: 5605

Exact text from the filing

January 17, 2024, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that, due to the appointment of Dorothy Clarke as the Company’s General Counsel, Ms. Clarke’s subsequent resignation from the committees of the Company’s Board of Directors (the “Board”) and the appointment of Sanjeev Luther as a member of the Board, the Company no longer complies with Nasdaq’s majority independent board and independent audit committee requirements as set forth in Nasdaq Listing Rule 5605

View on SEC.gov

Browse all listing & compliance notices →

Ernexa Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-002915

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.